Cannabis Rescheduling and Firearm Rights: Legal Status and Impact

Executive Summary

Cannabis rescheduling from Schedule I to Schedule III under the Controlled Substances Act does not restore Second Amendment firearm rights to cannabis users, creating a persistent legal conflict that affects millions of Americans. Despite the Drug Enforcement Administration's historic reclassification reducing cannabis to the same schedule as ketamine and anabolic steroids, federal firearm prohibitions under 18 U.S.C. § 922(g)(3) remain fully intact. This statute bars any person who is an "unlawful user of or addicted to any controlled substance" from possessing firearms or ammunition, and Schedule III substances remain controlled substances under federal law. The Bureau of Alcohol, Tobacco, Firearms and Explosives continues to enforce ATF Form 4473, which requires firearm purchasers to attest they are not unlawful users of controlled substances, with cannabis use—even in states where it is legal—constituting perjury and a federal felony punishable by up to 10 years imprisonment. The rescheduling creates a three-way tension between state cannabis legalization, federal drug scheduling, and constitutional firearm rights that courts, Congress, and regulatory agencies have yet to resolve. An estimated 55 million Americans who use cannabis in compliance with state law now face a choice between exercising their state-legal cannabis rights or their Second Amendment rights, but not both.

Why This Matters

The intersection of cannabis rescheduling and firearm rights affects constitutional liberties, public safety policy, criminal justice outcomes, and the daily lives of tens of millions of Americans across 38 states with medical cannabis programs and 24 states with adult-use legalization. The stakes involve fundamental constitutional questions. Second Amendment advocates argue that rescheduling should trigger a reassessment of firearm prohibitions, particularly after the Supreme Court's 2022 decision in New York State Rifle & Pistol Association v. Bruen established a new "text and history" standard for evaluating gun regulations. Civil liberties organizations contend that prohibiting firearm possession based solely on cannabis use—a substance now recognized by the federal government as having accepted medical uses—violates both Second Amendment rights and Fifth Amendment due process protections. The financial and commercial implications extend across multiple industries. The firearms industry serves an estimated 80 million gun owners nationwide, while the legal cannabis industry generated $28.4 billion in sales in 2024 according to industry analysts. The overlap between these consumer bases creates significant market friction. Medical cannabis patients, who numbered approximately 3.2 million registered individuals as of 2024, face particularly acute dilemmas when prescribed cannabis for conditions including chronic pain, PTSD, and epilepsy while also seeking firearms for home defense or sporting purposes. Law enforcement agencies confront operational challenges in enforcing federal prohibitions that conflict with state law. Federal prosecutors have discretion in charging decisions, creating geographic disparities in enforcement. The ATF conducted approximately 1.2 million background checks monthly in 2024, with Form 4473 violations representing a growing category of federal prosecutions. State and local police in legalized jurisdictions must navigate the tension between respecting state cannabis laws and cooperating with federal firearm enforcement. Veterans represent a particularly affected population. An estimated 20% of post-9/11 veterans report using cannabis, many for service-connected conditions including PTSD and traumatic brain injury. Veterans Affairs physicians can recommend but not prescribe cannabis due to federal restrictions, yet even a recommendation can trigger firearm prohibitions. Veterans advocacy organizations have identified this conflict as a barrier to both medical treatment and Second Amendment rights for those who served.

Background and History

The collision between cannabis prohibition and firearm rights emerged from separate legislative frameworks enacted decades apart, creating an unintended constitutional conflict that intensified as states began legalizing cannabis in the 1990s and 2000s.

The Controlled Substances Act and Schedule I Classification (1970)

Congress enacted the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, establishing a five-schedule classification system for drugs based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I, defined as substances with "no currently accepted medical use" and "high potential for abuse." This classification occurred despite the recommendation of the Shafer Commission, appointed by President Richard Nixon, which concluded in 1972 that cannabis should be decriminalized. The Schedule I designation placed cannabis alongside heroin, LSD, and peyote, creating the statutory foundation for the most restrictive federal controls.

The Gun Control Act and Prohibited Persons (1968)

Two years before the Controlled Substances Act, Congress passed the Gun Control Act of 1968 in response to the assassinations of President John F. Kennedy, Senator Robert F. Kennedy, and Dr. Martin Luther King Jr. Section 922(g) established nine categories of prohibited persons, including convicted felons, fugitives, and those adjudicated as mentally defective. Subsection (g)(3) prohibited firearm possession by any person "who is an unlawful user of or addicted to any controlled substance (as defined in section 102 of the Controlled Substances Act)." This cross-reference meant that the 1970 scheduling of cannabis automatically triggered firearm prohibitions for cannabis users, though this connection received little attention during an era when cannabis use was far less widespread and socially accepted.

State Medical Cannabis Laws (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, in 1996, becoming the first state to legalize medical cannabis. By 2012, 18 states and the District of Columbia had enacted medical cannabis programs. This created the first major tension between state law and federal firearm prohibitions. The ATF responded with an open letter to federal firearms licensees on September 21, 2011, clarifying that "any person who uses or is addicted to marijuana, regardless of whether his or her State has passed legislation authorizing marijuana use for medicinal purposes, is an unlawful user of or addicted to a controlled substance, and is prohibited by Federal law from possessing firearms or ammunition."

The Cole Memo and Federal Enforcement Discretion (2013)

Deputy Attorney General James Cole issued a memorandum on August 29, 2013, establishing enforcement priorities for federal cannabis prosecutions. The Cole Memo directed federal prosecutors to focus resources on preventing distribution to minors, revenue going to criminal enterprises, and diversion to non-legal states, effectively deprioritizing prosecution of state-compliant cannabis businesses and users. However, the memo explicitly stated it did not alter the application of federal firearms laws, leaving the prohibition under 18 U.S.C. § 922(g)(3) fully enforceable.

Wilson v. Lynch and the Ninth Circuit Decision (2016)

S. Rowan Wilson, a Nevada resident with a medical cannabis registry card, challenged the constitutionality of the federal firearm prohibition after a firearms dealer refused to sell her a gun based solely on her registry status. The U.S. Court of Appeals for the Ninth Circuit ruled on August 31, 2016, that the prohibition did not violate the Second Amendment, applying intermediate scrutiny and finding that Congress had a substantial interest in preventing gun violence and that the prohibition was reasonably related to that interest. The court held that "it is beyond dispute that illegal drug users, including marijuana users, are likely as a consequence of that use to experience altered or impaired mental states that affect their judgment and that can lead to irrational or unpredictable behavior." The Supreme Court denied certiorari on June 19, 2017, leaving the Ninth Circuit decision as controlling precedent in Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, Oregon, and Washington.

Sessions Memo Rescission of Cole Guidance (2018)

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, eliminating the formal federal enforcement discretion policy. The Sessions Memo returned charging decisions to individual U.S. Attorneys, creating uncertainty about federal prosecution priorities. However, practical enforcement patterns showed continued federal restraint in prosecuting state-compliant cannabis activity, with firearm-related prosecutions remaining a small subset of overall federal cannabis cases.

Adult-Use Legalization Expansion (2012-2024)

Colorado and Washington became the first states to legalize adult-use cannabis in 2012, with sales beginning in 2014. By 2024, 24 states, three territories, and the District of Columbia had legalized adult-use cannabis, with 38 states operating medical programs. This expansion dramatically increased the number of Americans facing the firearm prohibition, with an estimated 55 million adults reporting past-year cannabis use according to the National Survey on Drug Use and Health.

The Rescheduling Process (2022-2026)

President Joseph Biden directed the Department of Health and Human Services and the Attorney General to review cannabis scheduling on October 6, 2022. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on findings that cannabis has accepted medical uses and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, initiating a formal rulemaking process that included a public comment period receiving over 43,000 submissions. Following administrative law judge hearings and final review, the DEA published the final rule rescheduling cannabis to Schedule III under 21 C.F.R. § 1308.13, effective May 1, 2026.

Post-Rescheduling Firearm Law Status (2026)

The rescheduling to Schedule III did not alter the text of 18 U.S.C. § 922(g)(3), which prohibits firearm possession by unlawful users of "any controlled substance" without limitation to specific schedules. The ATF issued guidance on May 15, 2026, confirming that Form 4473 requirements remain unchanged and that cannabis use continues to constitute unlawful use of a controlled substance for purposes of federal firearm prohibitions. This guidance clarified that rescheduling affects tax treatment under Internal Revenue Code Section 280E and research restrictions, but does not modify the Gun Control Act's prohibited person categories.

Key Players

Bureau of Alcohol, Tobacco, Firearms and Explosives

The ATF administers and enforces federal firearm laws, including the prohibited person provisions of 18 U.S.C. § 922(g)(3), and maintains the National Instant Criminal Background Check System infrastructure. The bureau issues Form 4473, the Firearms Transaction Record required for all firearm purchases from licensed dealers, which includes Question 21.e asking: "Are you an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance?" The form includes a warning that "the use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside." ATF Industry Operations Investigators conduct compliance inspections of the approximately 78,000 federal firearms licensees nationwide, reviewing Form 4473 records for accuracy and completeness. The bureau has maintained consistent guidance that state cannabis legalization does not affect federal firearm prohibitions.

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule and reschedule controlled substances, subject to HHS recommendations on scientific and medical matters. The agency's 2026 rescheduling decision moved cannabis from Schedule I to Schedule III based on an eight-factor analysis examining abuse potential, scientific evidence, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance. DEA Administrator Anne Milgram emphasized in the final rule's preamble that rescheduling "does not legalize marijuana under federal law" and "does not change the fact that marijuana remains a controlled substance subject to applicable criminal prohibitions." The agency coordinates with ATF on enforcement matters involving both controlled substances and firearms.

Department of Justice

DOJ establishes federal prosecution priorities through U.S. Attorneys' offices in 94 federal judicial districts, with discretion to charge violations of both drug and firearm statutes. Following the 2018 rescission of the Cole Memo, prosecution patterns have varied by district, with some U.S. Attorneys maintaining de facto non-prosecution policies for state-compliant cannabis activity while others have pursued cases involving firearms and cannabis. The department's position, articulated in multiple court filings, maintains that Congress intended 18 U.S.C. § 922(g)(3) to apply to all controlled substances regardless of schedule. Deputy Attorney General Lisa Monaco testified before the Senate Judiciary Committee on March 12, 2026, that rescheduling "does not impact the Department's authority or obligation to enforce federal firearm laws as written by Congress."

Second Amendment Advocacy Organizations

Gun rights groups including the National Rifle Association, Firearms Policy Coalition, and Second Amendment Foundation have challenged the constitutionality of cannabis-based firearm prohibitions in multiple federal circuits. These organizations argue that post-Bruen jurisprudence requires the government to demonstrate a historical tradition of disarming individuals based on substance use, which they contend does not exist for cannabis. The Firearms Policy Coalition filed suit in the U.S. District Court for the Northern District of Texas on June 3, 2026, arguing that the continued prohibition after rescheduling violates the Second Amendment as applied to medical cannabis patients. The NRA has filed amicus briefs in multiple cases arguing that "law-abiding citizens who use cannabis in compliance with state medical programs pose no greater danger than those who consume alcohol, yet face lifetime firearm prohibitions."

Cannabis Industry and Advocacy Organizations

The National Cannabis Industry Association, National Organization for the Reform of Marijuana Laws, and Marijuana Policy Project have advocated for federal legislation to resolve the firearm rights conflict. These groups supported the rescheduling process but emphasized that Schedule III status does not address civil liberties concerns. NORML Legal Counsel Matthew Schweich stated in congressional testimony on April 8, 2026, that "rescheduling is a step forward for science and tax policy, but it does nothing for the millions of Americans who must choose between their medicine and their constitutional rights." The Cannabis Industry Association has estimated that the firearm prohibition affects business owners, employees, and investors in the legal cannabis sector, creating additional barriers to industry participation.

Veterans Organizations

Iraq and Afghanistan Veterans of America, Veterans of Foreign Wars, and American Legion posts have identified the cannabis-firearm conflict as a priority issue affecting veteran health and rights. These organizations note that many veterans use cannabis for PTSD, chronic pain, and other service-connected conditions, while also valuing firearm ownership for personal protection, hunting, and recreational shooting. IAVA Policy Director Travis Horr testified before the House Veterans' Affairs Committee on February 14, 2026, that "forcing veterans to choose between effective treatment and Second Amendment rights is unconscionable and counterproductive to both veteran health and public safety."

Legal and Regulatory Framework

The cannabis-firearm prohibition rests on the interaction of three federal statutes—the Controlled Substances Act, the Gun Control Act, and related criminal provisions—creating a complex legal structure that rescheduling does not dismantle. The core prohibition appears in 18 U.S.C. § 922(g)(3), which makes it "unlawful for any person who is an unlawful user of or addicted to any controlled substance (as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) to ship or transport in interstate or foreign commerce, or possess in or affecting commerce, any firearm or ammunition; or to receive any firearm or ammunition which has been shipped or transported in interstate or foreign commerce." Violations constitute felonies punishable by up to 10 years imprisonment under 18 U.S.C. § 924(a)(2). The statutory cross-reference to 21 U.S.C. § 802 incorporates the Controlled Substances Act's definition of "controlled substance" as "a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter." This definition encompasses all five schedules, meaning that rescheduling cannabis from Schedule I to Schedule III does not remove it from the category of controlled substances for purposes of the firearm prohibition. The term "unlawful user" lacks statutory definition, leaving interpretation to regulatory guidance and case law. The ATF's regulatory definition at 27 C.F.R. § 478.11 states that "a person who uses a controlled substance and has lost the power of self-control with reference to the use of controlled substance" qualifies as an unlawful user. Federal courts have interpreted this broadly, with the Fifth Circuit holding in United States v. Purdy (2001) that "regular use" constitutes unlawful use even without evidence of addiction or impairment at the time of firearm possession. The Ninth Circuit in United States v. Dugan (2011) found that use "with some regularity, and in close temporal proximity to the gun possession" satisfies the statute, establishing a temporal nexus requirement that varies by circuit. Form 4473, mandated by 27 C.F.R. § 478.124, operationalizes the prohibition at point of sale. Question 21.e requires purchasers to answer whether they are unlawful users of controlled substances, with the form explicitly stating that "the use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside." False answers constitute violations of 18 U.S.C. § 922(a)(6), which prohibits knowingly making false statements in connection with firearm acquisitions, and 18 U.S.C. § 1001, the general false statements statute. These violations carry penalties of up to 10 years imprisonment. The National Instant Criminal Background Check System, established by the Brady Handgun Violence Prevention Act and codified at 18 U.S.C. § 922(t), does not automatically flag cannabis users because most state medical cannabis registries are not accessible to the FBI's NICS database due to state privacy laws. This creates an enforcement gap where the prohibition relies primarily on self-reporting through Form 4473 rather than database checks. However, federal prosecutions can proceed based on evidence obtained through other means, including social media posts, odor during traffic stops, or statements to law enforcement. The Controlled Substances Act itself, at 21 U.S.C. § 812, establishes the scheduling framework that determines which substances trigger firearm prohibitions. Schedule III substances are defined as those with "a potential for abuse less than the substances listed in schedules I and II," "currently accepted medical use in treatment in the United States," and abuse that "may lead to moderate or low physical dependence or high psychological dependence." Cannabis now shares Schedule III with ketamine, anabolic steroids, buprenorphine, and certain barbiturates. Critically, possession of Schedule III substances without a valid prescription remains a federal crime under 21 U.S.C. § 844, punishable by up to one year imprisonment for first offenses. Because cannabis cannot be prescribed under federal law—only scheduled substances approved by the FDA can be prescribed—all cannabis possession remains "unlawful" for purposes of 18 U.S.C. § 922(g)(3). State constitutional provisions add another layer of complexity. Forty-four state constitutions contain right-to-bear-arms provisions, many with stronger protections than the Second Amendment. State courts in Kansas, Missouri, and Pennsylvania have issued rulings addressing whether state firearm rights extend to medical cannabis patients, with divergent outcomes. Kansas courts have held that federal law preempts state firearm rights in this context, while Missouri courts have found that state constitutional protections may limit state enforcement of federal prohibitions.

State-by-State Breakdown

State responses to the cannabis-firearm conflict vary widely, with some states enacting laws to protect medical cannabis patients' firearm rights under state law while others defer entirely to federal prohibitions.

Pennsylvania

Pennsylvania enacted the Medical Marijuana Act in 2016, establishing a registry of approximately 425,000 patients as of 2024. The state does not share registry information with federal authorities or the NICS database. Pennsylvania's Uniform Firearms Act, 18 Pa.C.S. § 6105, prohibits firearm possession by persons convicted of certain crimes or subject to protection-from-abuse orders, but does not include medical cannabis patients as a prohibited category under state law. However, federal law preempts state law, meaning Pennsylvania residents remain subject to federal prosecution. The Pennsylvania State Police have issued guidance that medical cannabis cardholders may apply for License to Carry Firearms permits under state law, but warned that federal prohibitions remain applicable.

Oklahoma

Oklahoma voters approved State Question 788 in 2018, creating one of the nation's most permissive medical cannabis programs with over 375,000 licensed patients. Oklahoma Statutes Title 63, Section 420 et seq. explicitly provides that medical cannabis license holders "shall not be denied the right to own, purchase or possess a firearm" under state law. However, this state protection does not shield patients from federal prosecution. Oklahoma has not enacted legislation prohibiting state law enforcement from cooperating with federal authorities on firearm-cannabis cases, creating potential for joint state-federal enforcement.

Missouri

Missouri's constitutional amendment legalizing medical cannabis, approved by voters in 2018, includes language stating that medical cannabis patients shall have "the same rights with respect to the possession, use, and cultivation of marijuana for medical use as are enjoyed by other Missouri citizens with respect to other medications prescribed or recommended by a physician." The Missouri Department of Health and Senior Services maintains a confidential registry of approximately 240,000 patients. Missouri Revised Statutes Section 571.070 does not list medical cannabis use as a disqualifying factor for concealed carry permits. However, the state's concealed carry application asks whether applicants are "an unlawful user of, or addicted to, any controlled substance," mirroring federal language.

Arizona

Arizona legalized medical cannabis in 2010 and adult-use cannabis in 2020. Arizona Revised Statutes Section 36-2802 provides that medical cannabis cardholders "may not be denied any right or privilege" based solely on cardholder status. The Arizona Department of Public Safety maintains a confidential registry not shared with federal authorities. However, Arizona's concealed weapons permit application, governed by A.R.S. § 13-3112, requires applicants to certify they are not prohibited possessors under federal law. Arizona courts have held that state protections do not override federal prohibitions, leaving patients vulnerable to federal prosecution.

Florida

Florida's medical cannabis program, established by constitutional amendment in 2016, serves over 800,000 registered patients, the largest state program by enrollment. Florida Statutes Section 790.065 governs firearm background checks and incorporates federal prohibited person categories by reference. The Florida Department of Agriculture and Consumer Services, which issues concealed weapon licenses, has taken the position that medical cannabis cardholders are federally prohibited persons ineligible for state licenses. This interpretation has been challenged in state court, with litigation ongoing as of 2026.

Illinois

Illinois legalized adult-use cannabis in 2019 and maintains a medical program serving approximately 150,000 patients. Illinois law at 410 ILCS 130/10 prohibits the state from maintaining a registry that could be used to deny firearm rights, instead using a verification system that does not create a searchable database of patient identities. Illinois's Firearm Owners Identification Card system, required for all firearm possession in the state, does not automatically revoke cards based on medical cannabis participation. However, the FOID application requires applicants to certify they are not federally prohibited persons.

Hawaii

Hawaii became the first state to cross-reference its medical cannabis registry with firearm registrations, sending letters to registered patients in 2017 instructing them to surrender firearms. This policy, based on Hawaii Revised Statutes Section 134-7, which prohibits firearm permits for "fugitives from justice" and "persons who are unlawful users of or addicted to any controlled substance," sparked national controversy. Following legal challenges and public backlash, Hawaii modified its policy to conduct individualized assessments rather than automatic disqualifications, though the legal authority for such disqualifications remains contested.

Federal Enclaves and Territories

The District of Columbia legalized medical cannabis in 2010 and adult-use possession in 2014, though commercial sales remain prohibited by congressional appropriations riders. D.C. Code Section 7-1671.08 provides that medical cannabis patients shall not be subject to arrest or prosecution under D.C. law, but federal law applies with full force in the District. Federal enclaves including military bases, national parks, and federal buildings remain subject to exclusive federal jurisdiction where state cannabis legalization provides no protection and federal firearm prohibitions apply without exception.

Market and Business Implications

The persistent firearm prohibition after rescheduling creates significant economic friction across the cannabis industry, firearms sector, and ancillary businesses serving both markets. Cannabis industry participants face unique vulnerabilities regarding firearm possession. Dispensary owners, cultivators, and processors frequently seek firearms for business security given the cash-intensive nature of cannabis operations and federal banking restrictions that limit electronic payment options. However, active participation in the cannabis industry—even in compliance with state law—constitutes "unlawful use" of controlled substances for purposes of 18 U.S.C. § 922(g)(3) according to ATF guidance. This creates a paradox where businesses most in need of armed security are least able to legally possess firearms themselves, forcing reliance on third-party security contractors. The security services market for cannabis businesses has grown to an estimated $1.8 billion annually, with armed guard services commanding premium rates. However, security personnel who use cannabis—even off-duty in compliance with state law—face the same federal prohibitions, limiting the labor pool for armed security positions. Some multi-state operators have implemented drug testing policies prohibiting cannabis use by security staff, creating the anomaly of cannabis businesses firing employees for using their own products. Investment and ownership structures face complications from the firearm prohibition. Private equity firms and institutional investors conducting due diligence on cannabis acquisitions must assess whether principals' firearm ownership creates federal criminal exposure. Some investment agreements now include representations and warranties regarding firearm possession and controlled substance use. The firearm prohibition has emerged as a factor in corporate governance decisions, with some boards requiring executives to divest firearms or abstain from cannabis use to minimize legal risk. The firearms industry confronts its own challenges from the cannabis-firearm conflict. Federal firearms licensees who sell to known cannabis users face potential license revocation under 18 U.S.C. § 923(e) for willful violations of the Gun Control Act. This has led some dealers in legalized states to implement screening policies, including questioning customers about cannabis use beyond the Form 4473 requirements. However, such questioning creates customer relations challenges and potential discrimination claims. The National Shooting Sports Foundation has estimated that the cannabis-firearm conflict affects 15-20% of potential firearm purchasers in adult-use states, representing significant foregone sales. Ancillary businesses including shooting ranges, hunting outfitters, and firearms training facilities face liability questions when serving customers in legalized cannabis states. Some ranges have implemented policies prohibiting visibly impaired shooters, while others have avoided cannabis-specific policies to prevent discrimination claims. Insurance carriers have begun excluding cannabis-related incidents from general liability policies, creating coverage gaps. The concealed carry permit market has experienced disruption in states with shall-issue permitting systems that require issuance to all non-prohibited applicants. Permit instructors and processing agencies must navigate the tension between state laws that do not prohibit medical cannabis patients and federal law that does. Some states have seen permit application rates decline among medical cannabis patients following publicity about the federal prohibition. Banking and financial services complications extend beyond the cannabis industry itself to affect firearms businesses serving cannabis-adjacent customers. Some banks have implemented enhanced due diligence for firearms dealers in legalized states, concerned about facilitating transactions that could involve federally prohibited persons. This has contributed to the broader "Operation Choke Point 2.0" concerns in the firearms industry regarding banking access. The rescheduling to Schedule III provides significant tax benefits to cannabis businesses by eliminating the application of Internal Revenue Code Section 280E, which prohibits deducting ordinary business expenses for trafficking in Schedule I or II substances. This tax change could improve cannabis business profitability by 20-40% according to industry analysts, potentially increasing business valuations and investment returns. However, the improved financial position does not resolve the firearm prohibition, creating a disconnect where cannabis businesses gain tax parity with other industries while their owners and employees remain subject to unique constitutional restrictions.

What Experts Say

Legal scholars, constitutional law experts, and policy analysts have offered divergent assessments of whether rescheduling should affect firearm rights analysis under post-Bruen Second Amendment jurisprudence. Professor David Kopel of Denver University Sturm College of Law has argued that the historical tradition required under Bruen does not support disarming cannabis users. According to Kopel's research on founding-era firearm regulations, colonial and early American laws focused on disarming those who posed imminent violent threats, not those who used substances that were legal at the time. Kopel noted in a 2026 law review article that cannabis was legal and widely available in the United States until the early 20th century, with no corresponding firearm prohibitions, suggesting the current prohibition lacks historical foundation. Professor Robert Cottrol of George Washington University Law School has taken a more nuanced position, arguing that while historical tradition may not support blanket prohibitions, the government retains authority to disarm individuals who pose demonstrable risks. Cottrol has suggested that the prohibition might survive constitutional scrutiny if applied only to individuals with evidence of impairment or dangerous behavior, rather than categorical disarmament based on substance use alone. Former ATF Deputy Director Ronald Turk has defended the current prohibition on public safety grounds, stating in congressional testimony that "the combination of firearms and mind-altering substances presents unacceptable risks regardless of the substance's schedule." Turk has pointed to ATF data showing that substance abuse appears as a factor in a significant percentage of firearm homicides and suicides, though he acknowledged that cannabis-specific data is limited. Dr. Ziva Cooper, Director of the UCLA Center for Cannabis and Cannabinoids, has challenged the scientific basis for treating cannabis users as categorically dangerous. According to Cooper's research on cannabis pharmacology, the acute impairing effects of cannabis are time-limited and dose-dependent, unlike the chronic impairment associated with alcohol use disorder or opioid addiction. Cooper has testified that "there is no scientific basis for treating occasional cannabis users as permanently unfit for firearm possession when we allow alcohol users to possess firearms." Professor Nicholas Johnson of Fordham University School of Law has examined the racial justice implications of the cannabis-firearm prohibition, noting that cannabis prohibition has been enforced disproportionately against Black and Latino communities. Johnson's research indicates that the firearm prohibition extends these disparities, creating a pathway for felony prosecution of minority gun owners at higher rates than white gun owners in states with legalized cannabis. Sam Paredes, Executive Director of Gun Owners of California, has called the continued prohibition after rescheduling "an absurdity that demonstrates the need for comprehensive federal cannabis reform." According to Paredes, the current framework forces law-abiding citizens to choose between state-legal conduct and constitutional rights, a choice the government should not be able to impose. Paul Armentano, Deputy Director of NORML, has emphasized that rescheduling alone cannot resolve the conflict, stating that "only congressional action to remove cannabis from the Controlled Substances Act entirely, or to explicitly exempt cannabis from firearm prohibitions, will restore rights to the millions of Americans caught in this legal trap."

What's Next

The cannabis-firearm conflict will likely be resolved through some combination of litigation, congressional action, and regulatory reinterpretation, with multiple pathways forward emerging in 2026 and beyond. Litigation challenging the prohibition post-rescheduling is advancing in multiple federal circuits. The Fifth Circuit is considering a challenge brought by medical cannabis patients in Texas arguing that Bruen's text-and-history standard invalidates the prohibition as applied to them. Oral arguments occurred on April 15, 2026, with a decision expected by fall 2026. The Sixth Circuit has a similar case pending from Ohio, while the Tenth Circuit is reviewing a challenge from Colorado involving adult-use consumers. These cases could create circuit splits that increase the likelihood of Supreme Court review. Congressional legislation offers another pathway. The Marijuana Opportunity Reinvestment and Expungement Act, reintroduced in the 119th Congress, would deschedule cannabis entirely and expunge prior federal cannabis convictions. Section 9 of the bill explicitly provides that cannabis use would no longer constitute grounds for firearm prohibition. However, the bill faces uncertain prospects in a divided Congress. A narrower alternative, the GRAM Act (Gun Rights and Marijuana Act), would amend 18 U.S.C. § 922(g)(3) to exclude state-legal cannabis use from the definition of "unlawful user." This targeted approach may have better prospects for bipartisan support. Administrative action by the ATF could modify enforcement priorities or interpretations of "unlawful user" without congressional action. The bureau could issue guidance clarifying that infrequent cannabis use, or use that occurred in the distant past, does not constitute being an "unlawful user" in the present tense. Such guidance would parallel ATF's treatment of alcohol, where past alcohol abuse does not create permanent prohibition absent ongoing addiction. However, ATF officials have indicated reluctance to make such changes without clear congressional direction. State-level responses may continue to diverge, with some states enacting stronger protections for cannabis users' firearm rights under state law while others maintain alignment with federal prohibitions. Oklahoma and Missouri may serve as models for state constitutional amendments explicitly protecting medical cannabis patients' firearm rights, though such protections cannot override federal law. The 2026 election cycle may influence the trajectory of reform. Presidential candidates have been questioned about their positions on the cannabis-